Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

terin levels occurred within the first cycle of custirsen treatment when compared to levels in the docetaxel arm, indicating on-target biological activity of custirsen; - Measurable stable disease was higher (77% in custirsen plus docetaxel arm versus 50% in docetaxel arm) and disease progression, without any response to therapy, was lower (4% in custirsen plus docetaxel arm versus 17% in docetaxel arm). The incidence of overall objective response was comparable; - Because the primary endpoint of the study was achieved and survival benefit was observed, custirsen warrants further study in Phase 3 trials.

"Despite the number of new treatment options for patients with advanced prostate cancer, many patients will eventually experience disease progression. We believe custirsen has the potential to reduce treatment resistance thereby increasing the efficacy of various therapeutic agents such as docetaxel, and are hopeful this will be confirmed through the Phase 3 development program," said Scott Cormack, president and CEO of OncoGenex.

In 2009, Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. entered into a global license and collaboration agreement to develop and commercialize custirsen.

Phase 2 Study Design

In this Phase 2 study, 82 patients were randomized to one of two treatment arms to receive either 640 mg per week of custirsen by intravenous infusion in combination with docetaxel/prednisone or docetaxel/prednisone alone. Patients in both treatment arms received therapy until disease progression, toxicity or completion of ten 3-week cycles of therapy. The primary endpoint of the trial was to achieve a 50% reduction in PSA from baseline in over 50% of the patients treated with custirsen plus docetaxel. Secondary endpoints included determining objective response and duration of response in those patients with measurable disease at baseline, determining the tolerability and toxicity of weekly custirsen in combinati
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that ... an e-Journal and producer of Food Labs Conference ... for the co-location of Food Labs Conference to be held ... registration fee to attend the two-day Food Lab Conference, March ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Trius Therapeutics, Inc. today announced that it has been ... the Defense Threat Reduction Agency (DTRA), an agency within the ... directed against gram-negative bacterial pathogens. Trius may receive up to ... the new DTRA contract, which is funded as part of ...
... the United States, over the past four decades, have ... them involving bombs or explosives, says a new report ... Study of Terrorism and Responses to Terrorism (START). ... from the Center,s Global Terrorism Database (GTD), the world,s ...
... , May 18 Patient and professional ... marketplace on new medicines. Effectively collaborating with advocacy groups ... and is especially critical for socially sensitive conditions/therapies. " ... " is a 125-page report from Best Practices, LLC ...
Cached Biology Technology:Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics 2Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics 3US terror concentrated in New York City; bombs weapon of choice 2Educating the Marketplace Through Collaborations with Patient Advocacy Groups 2Educating the Marketplace Through Collaborations with Patient Advocacy Groups 3
(Date:4/18/2014)... [Brown University] Asteroid and comet impacts can cause ... regional or even global scales. But new research from ... signatures of ancient life at the time of an ... Pete Schultz has found fragments of leaves and preserved ... ancient impacts in Argentina. The material could provide a ...
(Date:4/17/2014)... was a word for chili peppers. Information about archaeological ... a study of the appearance of words for chili ... jalapeos were domesticated and highlight the value of multi-proxy ... et al.) of nine papers presented in a special ... Academy of Sciences on plant and animal domestication ...
(Date:4/17/2014)... ALBUQUERQUE, N.M. A credit-card-sized anthrax detection cartridge developed ... small business makes testing safer, easier, faster and cheaper. ... causes anthrax, is commonly found in soils all over ... illness in both humans and animals. The bacteria can ... to B. anthracis may occur through skin ...
Breaking Biology News(10 mins):Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Chickens to chili peppers 2Chickens to chili peppers 3Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... the mechanism that binds skin cells tightly together, which ... and debilitating skin diseases and also lethal heart defects. ... Sciences, has found that the glue molecules bind only ... very tough, resilient structure. Further investigation on why the ...
... NASA,s newest Earth-observing research mission is nearing launch. The ... sun and tiny atmospheric particles called aerosols affect Earth,s ... solar measurements needed to address key uncertainties about climate ... Vandenberg Air Force Base in California on Feb. 23 ...
... little more than a conventional photocopier and transparency film, ... local Cambridge high school physics teacher invented the process; ... Harvard,s School of Engineering and Applied Sciences (SEAS), students ... The Microfluidics Lab, developed by Dr. Anas Chalah, Director ...
Cached Biology News:Cell binding discovery brings hope to those with skin and heart problems 2NASA prepares to launch next Earth-observing satellite mission 2NASA prepares to launch next Earth-observing satellite mission 3Simple, ingenious way to create lab-on-a-chip devices could become a model for teaching and research 2Simple, ingenious way to create lab-on-a-chip devices could become a model for teaching and research 3
Purified anti-PI3K p110 delta...
Biotin anti-mouse Ly-49C/F/I/H...
... Antigen Afinity Purified Tyrosine Hydroxylase ... antibody was raised against synthetic ... residues surrounding the phospho-Ser40 of ... antibody was purified by sequential ...
Mouse Wnt-9b Biotinylated Affinity Purified PAb ENTREZ GeneID: 22412...
Biology Products: